a r t i c l e s IFN-β is widely prescribed for the treatment of RRMS. However, only about two thirds of patients with RRMS respond to treatment 1 . Furthermore, IFN-β can exacerbate symptoms in some individuals 2 . Therefore, we analyzed how cytokine networks, particularly the T H 1 and T H 17 pathways, influence IFN-β therapy in RRMS and in EAE.
There are many purported mechanisms of action of IFN-β in MS [3] [4] [5] [6] [7] [8] . IFN-β reduces T H 1 pathologies by blocking the proinflammatory properties of IFN-γ and IL- 12 (refs. 6,7) . IFN-β also inhibits differentiation of T H 17 cells 5, 8, 9 . Besides inhibition of inflammation, IFN-β leads to increased production of the regulatory cytokines IL-10, IL-27 and IL-4 (refs. 4, 8, 10) . However, a full understanding of why IFN-β therapy works in some people with RRMS and not in others is still unknown.
RESULTS

IFN-b blocks mouse T H 17 differentiation
First, we analyzed the effect of IFN-β on T H 17 differentiation of mouse CD4 + T cells stimulated with IL-6, transforming growth factor-β (TGF-β) and antigen-presenting cells (APCs) 11 . IFN-β reduced T H 17 differentiation (Fig. 1a ). This decrease in T H 17 differentiation was not due to inhibition of T cell proliferation (data not shown).
In mice, IL-23 has a key role in driving effector and memory T H 17 cell function [11] [12] [13] [14] . However, naive cells respond weakly to IL-23 and require IL-6 and TGF-β to produce IL-17 (refs. 11,12) . We found that IFN-β decreased IL-17 production in naive CD4 + T cells stimulated with IL-6 and TGF-β in the presence of APCs (Fig. 1b) . Similarly, IFN-β attenuated IL-17 in effector and memory cells stimulated with either IL-6 and TGF-β or IL-23 alone (Fig. 1b) . This indicates that IFN-β decreases early and late stage T H 17 differentiation.
IFN-β signaling activates assembly of the interferon-stimulated gene factor-3 (ISGF-3) complex, comprised of signal transducer and activator of transcription-1 (STAT1), STAT2, interferon regulatory factor-9 (ref. 15) . We found that IFN-β failed to suppress T H 17 differentiation of Stat1 −/− mouse CD4 + T cells, implying that suppression of the T H 17 response is mediated by ISGF-3 signaling (Fig. 1c) . activity was increased and prolonged when we used both IFN-β and IFN-γ together compared to either cytokine alone ( Supplementary  Fig. 1a) . Additionally, the intensity and duration of STAT1 activation was reduced in Ifngr1 −/− CD4 + T cells stimulated with IFN-β as compared with wild-type (WT) T cells (Supplementary Fig. 1b ).
Next, we tested whether IFN-β requires IFN-γ signaling to inhibit T H 17 differentiation. We examined the effect of IFN-β on CD4 + T cells stimulated with IL-6, TGF-β and APCs in the presence or absence of neutralizing antibody to IFN-γ. Without IFN-γ neutralization, IFN-β lowered the frequency of IL-17-expressing T cells by 60% (Fig. 1d) . However, when IFN-γ was neutralized, the ability of IFN-β to inhibit IL-17 was reduced by 24% (Fig. 1d) . Neutralizing IFN-γ in the absence of IFN-β increased the frequency of IL-17 + CD4 + cells (Fig. 1d) . This is probably due to the inhibition of T H 17 differentiation by IFN-γ. Two other cytokines, IL-10 and IL-27, have been implicated in the inhibition of T H 17 differentiation 10, 19 . Neutralization of IL-10 or IL-27 did not affect the ability of IFN-β to inhibit IL-17 expression (Fig. 1d) .
IFN-β and IFN-γ may suppress IL-17 production in CD4 + T cells by acting on either T cells or APCs. We found that IFN-β inhibited IL-17 production in WT CD4 + cells cultured with WT APCs or Ifngr1 −/− APCs (Fig. 1e) . In contrast, IL-17 production was not inhibited in Ifngr1 −/− CD4 + T cells when cultured with either WT or Ifngr1 −/− APCs (Fig. 1e) . Additionally, we found that IFN-β alone did not inhibit IL-17 production in purified naive CD4 + cells ( Supplementary  Fig. 2a) . T H 17 inhibition probably requires the synergistic effects of IFN-β and IFN-γ. Indeed, we found that IFN-β or IFN-γ alone could not attenuate IL-17 production, but IFN-β and IFN-γ together lowered IL-17 production significantly (Fig. 1f) . 20, 21 . In nonpolarizing conditions, IFN-β induces IFN-γ expression in CD4 + cells in the presence (Fig. 2a) or absence (Supplementary Fig. 2b ) of APCs. However, IFN-β had no substantial effect on IFN-γ production when T cells were cultured in T H 1-skewing or T H 17-skewing conditions (Fig. 2a) . We next examined the cooperative effects of IFN-β and IFN-γ on T H 1 differentiation. In nonpolarizing conditions, IFN-β induced IFN-γ production equally in WT and Ifngr1 −/− CD4 cells cultured with WT APCs (Fig. 2b) , but IFN-γ production was reduced when CD4+ cells were cultured with Ifngr1 −/− APCs (Fig. 2b) . During T H 1 polarization, IFN-γ production was not affected by IFN-β or IFN-γ signaling (Fig. 2c) .
Effects of IFN-b on mouse T H 1 cells and regulatory T cells IFN-β induces T H 1 differentiation
The development of T H 17 cells is closely linked to regulatory T cells (T reg cells) 11, 12, 22 . Therefore, we explored the possibility that IFN-β inhibits T H 17 differentiation through an effect on Foxp3 + T reg cell development. However, we found that IFN-β did not induce the development of Foxp3 + T reg cells during T H 17 differentiation and had no effect on T reg cells development in cultures with TGF-β in the absence of IL-6 (Supplementary Fig. 3 ).
IFN-b increases IL-10 production in mouse CD4 + T cells
Individuals with multiple sclerosis who respond to IFN-β have increased IL-10 production after treatment 23, 24 . Therefore, we investigated whether IFN-β regulates IL-10 production during mouse T helper cell differentiation. We found that IFN-β increased IL-10 production in nonpolarizing T H 1 and T H 17 culture conditions (Fig. 2d) . However, upon incubation with IFN-β, cells in both the T H 1 and the nonpolarizing culture conditions showed markedly higher amounts of IL-10 as compared to the T H 17 conditions (Fig. 2d) . 
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We next explored whether IFN-β works synergistically with IFN-γ to upregulate IL-10. When we neutralized IFN-γ in nonpolarizing (Fig. 2e) , T H 1 ( Supplementary Fig. 4a ) and T H 17 ( Supplementary Fig. 4b ) cultures, upregulation of IL-10 by IFN-β was impaired. Furthermore, IL-10 production was impaired when we disrupted IFN-γ signaling in either CD4 + T cells or APCs, indicating that IL-10 induction by IFN-β requires IFN-γ signaling in CD4 + T cells and APCs (Fig. 2f) . Upregulation of IL-10 may promote an autocrine loop, further increasing the expression of IL-10. We found that neutralizing IL-10 had no effect on expression of IL-10 ( Fig. 2e and Supplementary Fig. 4 ).
IFN-b indirectly induces IL-10 production in mouse CD4 + T cells
Because IFN-β and IFN-γ directly inhibit IL-17 production in CD4 + T cells, we hypothesized that there is a similar effect on IL-10. We found that IFN-β alone had no effect on IL-10 production from purified CD4 + cells cultured without APCs in all conditions ( Supplementary  Fig. 2c ), including nonpolarizing and T H 1 conditions (where large amounts of IFN-γ are produced; Supplementary Fig. 2b) . Also, the addition of IFN-γ with IFN-β to purified CD4 + cells did not significantly increase IL-10 production (Fig. 2g) .
IL-27, which is produced by APCs, induces IL-10 in CD4 + T cells 10, 25 . Furthermore, IFN-β induces IL-27. Therefore, we analyzed the effect IFN-β has on IL-27 production. We found that in both nonpolarizing and T H 1 conditions, IL-27 was substantially upregulated by IFN-β compared to T H 17 conditions ( Supplementary  Fig. 5a ). Furthermore, we found that neutralizing IFN-γ inhibited IL-27 production ( Supplementary Fig. 5b,c) .
Effects of IFN-b on antigen-driven mouse T H differentiation
Next we assessed the effects of IFN-β on T H 1 and T H 17 differentiation during myelin oligodendrocyte glycoprotein (MOG) peptide re-stimulation. We re-stimulated T cells isolated from the draining lymph nodes of MOG-immunized mice with MOG peptide and either IL-12 or IL-23, to polarize cells to the T H 1 or T H 17 phenotype, respectively, and measured the concentration of cytokines and chemokines in culture supernatants by Luminex and ELISA (Supplementary Fig. 6 ). IFN-β considerably reduced IL-17 production in T H 17 cultures, markedly induced IL-10 production in T H 1 cells but not in T H 17 cells and had no significant effect on IFN-γ production ( Supplementary Fig. 6a-c) .
In addition, IFN-β did not upregulate IL-4 and TGF-β, two cytokines that have been implicated in regulating autoimmunity ( Supplementary  Fig. 6d,i) . Also of note, under T H 1 conditions, IFN-β induced tumor necrosis factor α, IL-6, IL-1α and IL-1β ( Supplementary Fig. 6e-h) . Under T H 17 culture conditions, IFN-β inhibited expression of the chemokines granulocyte colony-stimulating factor and monocyte chemotactic protein-1 (Supplementary Fig. 6n,o) . 
IFN-b is effective in T H 1 EAE but exacerbates T H 17 EAE
Our in vitro experiments demonstrate that IFN-β has antiinflammatory effects in T H 1 and T H 17 differentiation. This led us to examine whether IFN-β would be effective in treating EAE induced by T H 1 or T H 17 cells. We found considerable differences in the effect of IFN-β treatment on EAE induced by adoptive transfer of T H 1 and T H 17 cells. In C57BL/6 mice, IFN-β treatment significantly attenuated the progression of EAE symptoms in T H 1-induced EAE (Fig. 3a) , but, in contrast, the symptoms of T H 17-induced EAE were exacerbated by IFN-β treatment (Fig. 3b) . This was not a strain-dependent phenomenon, as we observed a similar effect in proteolipid protein induced EAE in the SJL mouse model (Supplementary Fig. 7a,b) . In accordance with the clinical course of EAE, histological analysis showed that IFN-β treatment blocked inflammation in the spinal cords of mice with T H 1-induced EAE but not in T H 17-induced EAE (Fig. 3c) .
Next we assessed the amount of IFN-γ, IL-17 and IL-10 produced in the central nervous system (CNS) 45 d after adoptive transfer of T cells. The frequency of CD4 + T cells producing IL-17 and IFN-γ in the spinal cord was lower after IFN-β treatment of mice with T H 1-induced EAE, but in mice with T H 17-induced EAE both T H 1 and T H 17 cells frequencies were elevated after IFN-β treatment (Fig. 3d,e) . IL-10-expressing CD4 + cell frequencies, in contrast, were decreased in the spinal cords of mice with T H 1 or T H 17 disease after IFN-β treatment (Fig. 3f) .
We then assessed the effects IFN-β treatment on splenic T cells isolated 45 d after adoptive transfer of T cells. In both T H 1-induced and T H 17-induced disease, IFN-γ production remained unchanged with IFN-β treatment (Fig. 3g) . However, IFN-β had differential effects on IL-17 and IL-10 in these disease models. In T H 1-induced EAE, the amount of IL-17 produced by splenic T cells was low, and treatment with IFN-β did not affect the production of this cytokine (Fig. 3h) . However, in T H 17-induced EAE, splenic T cells produced higher amounts of IL-17 compared to T H 1-induced EAE, and, unexpectedly, IL-17 abundance was significantly lower in the mice with T H 17-induced disease treated with IFN-β (Fig. 3h) . In contrast, IL-10 production from splenic T cells from mice with T H 1-induced disease was significantly elevated by treatment with IFN-β, but in mice with T H 17-induced EAE, IL-10 production remained very low after treatment (Fig. 3i) .
IFN-b treatment requires IFN-g to suppress EAE
Because IFN-β is highly effective in T H 1-induced EAE and because we found that IFN-β requires IFN-γ to suppress IL-17 and induce IL-10 in cultures, we speculated that effective IFN-β treatment for active EAE requires IFN-γ. To explore this hypothesis, we tested the efficacy of IFN-β treatment of MOG -induced EAE in C57BL/6 mice and Ifngr1 −/− mice. Daily injections of Rebif (a form of IFN-β1a), a popular IFN-β treatment, beginning 7 d after EAE induction, significantly delayed the onset and reduced the severity of EAE symptoms in the C57BL/6 mice (Fig. 4a) . This protective effect of IFN-β treatment was transient, as the mice developed severe symptoms after the withdrawal of treatment at 18 d after induction of the disease. In contrast to the results in C57BL/6 mice, IFN-β treatment had no effect on the development of disease in Ifngr1 −/− mice (Fig. 4b) . Similarly to Rebif treatment, treatment with recombinant mouse IFN-β attenuated EAE in C57BL/6 mice ( Supplementary Fig. 7c ) but not in Ifngr1 −/− mice (Supplementary Fig. 7d ).
Mice were treated daily with IFN-β from day 0 to day 6 after induction of EAE to model disease prevention. IFN-β treatment was modestly protective in C57BL/6 mice (Fig. 4c) , whereas Ifngr1 −/− mice had a trend toward more severe symptoms when treated with IFN-β (Fig. 4d) . This is similar to the effect of IFN-β after adoptive transfer of T H 17 cells (Fig. 3b) . Next we tested whether IFN-β treatment can reverse the progression of EAE after the onset of symptoms. We treated C57BL/6 and Ifngr1 −/− mice with recombinant mouse IFN-β when they attained a clinical score of 2 or 3. We found that recombinant mouse IFN-β treatment attenuated the progression of symptoms in C57BL/6 mice compared to PBS treated mice (Supplementary Fig. 7e) . 
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In accordance with the other regimens, IFN-β did not attenuate the disease in the Ifngr1 −/− mice (Supplementary Fig. 7f ).
Our in vitro data showed that cooperative signaling of IFN-β and IFN-γ indirectly induces IL-10 in CD4 + T cells via APCs (Fig. 2f) . To test whether this occurs in disease, we induced EAE in Ifngr1 −/− recipient mice by transferring WT encephalitogenic T H 1 cells and then treated the mice with recombinant mouse IFN-β or PBS every second day from day 0 to 10. We found that the recipient mice treated with IFN-β showed severe acute clinical symptoms that were substantially worse compared to the PBS-treated mice (Fig. 4e) .
In the CNS, C57BL/6 mice treated with IFN-β had low frequencies of T H 1 and T H 17 cytokine-expressing CD4 + T cells, as well as low frequencies of the population of CD4 + cells expressing both IL-17 and IFN-γ in the spinal cord, (Supplementary Fig. 8a ) brainstem and cerebellum (Supplementary Fig. 8b ) 12 d after induction of disease. In contrast, IFN-β treatment increased the frequencies of these T helper populations in the CNS of Ifngr1 −/− mice ( Supplementary Fig. 8a,b) .
Effect of IFN-b on human T H differentiation
To confirm the observed effects of IFN-β on human T H differentiation, we stimulated naive CD4 + T cells from four healthy donors for 5 and 11 d in nonpolarizing, T H 1-polarizing and T H 17-polarizing conditions in the presence or absence of IFN-β (Fig. 5) . IFN-β had no effect on IFN-γ production in all of the culture conditions after 5 or 11 d of culture (Fig. 5a,d) . IL-17 production was also not modulated by IFN-β after 5 d of culture (Fig. 5b) . However, by day 11, IFN-β inhibited IL-17 production during T H 17 differentiation in cells from three donors (578 ng ml −1 to 85 ng ml −1 , 696 ng ml −1 to 304 ng ml −1 , 284 ng ml −1 to 90 ng ml −1 ), whereas in cells from one donor IFN-β increased IL-17 production (385 pg ml −1 to 998 pg ml −1 ) (Fig. 5e) . During T H 1 polarization, IFN-β significantly increased IL-10 production by day 5 (Fig. 5c) in cells from all donors, and the induction of IL-10 was greater in T H 1-polarizing conditions compared to the nonpolarizing and T H 17 polarizing conditions on both day 5 and day 11 (Fig. 5c,f) .
Cytokine profile in people with RRMS before IFN-b treatment
We analyzed the pretreatment serum concentrations of 28 cytokines and chemokines in subjects with RRMS. We classified 12 subjects as responders and 14 as nonresponders to IFN-β treatment. Nonresponders have an exacerbated disease course in terms of both their relapse rate and their steroid usage. Steroids are used in the clinic when there is acute neurologic deterioration. The median relapse rate in the 2 years after initiation of IFN-β treatment in the nonresponders was two, whereas it was zero in the responder population (Supplementary Table 1) . Likewise, the median number of steroid interventions was two in the nonresponders and zero in the responders (Supplementary Table 1 ). Cluster analysis of the cytokine profiles grouped six nonresponders together (Fig. 6a) . This group of nonresponders had significantly elevated serum concentrations of both IL-17F and IFN-β compared to the responders (Fig. 6b,c) . Furthermore, there was a marked correlation with IL-17F and IFN-β concentrations in the serum of responders, nonresponders and healthy individuals (Supplementary Fig. 9a ). We did not find this correlation when comparing IL-17F or IFN-β to macrophage inflammatory protein-1β ( Supplementary Fig. 9b,c) or other analytes (data not shown).
DISCUSSION
IFN-β is one of the most widely used treatments for multiple sclerosis. However, a major limitation with IFN-β is that a 30%-50% of patients with multiple sclerosis do not respond to IFN-β therapy. Therefore, it is desirable to identify responders and nonresponders before the initiation of treatment. In a series of experiments in mice, we identified that mice with T H 1-induced EAE benefit from IFN-β treatment with a reduction in the degree of disability, whereas mice with T H 17-induced EAE do not respond, and their disease worsens.
In T H 1-driven EAE, induction of the anti-inflammatory cytokine IL-10 was increased with beneficial IFN-β treatment. Because IFN-β treatment inhibited T H 1-driven EAE, we speculated that effective IFN-β treatment depends on high IFN-γ levels during EAE. In fact, IFN-β was effective in treating active EAE in C57BL/6 mice but worsened EAE in Ifngr1 −/− mice. Furthermore, when we induced EAE by passive transfer of C57BL/6 T H 1 cells into Ifngr1 −/− recipient mice, IFN-γ influenced a broad range of cells in its complex interactions with IFN-β. Cell culture experiments, concordant with in vivo studies of EAE, revealed that the induction of IL-10 by IFN-β in T cells requires APCs and cooperative IFN-γ signaling, indicating that the APCs were the target of this activity of IFN-β. A popular speculation on the mechanism of IFN-β treatment is that it attenuates disease by inhibiting the differentiation of T H 17 cells 5, 8, 26 . We find that IFN-β inhibits IL-17 production in vitro and in EAE, yet IFN-β is ineffective in treating T H 17-induced EAE and worsens symptoms in these mice.
In RRMS, a subset of nonresponders had high serum concentrations of the T H 17 cytokine IL-17F before IFN-β therapy was initiated. IL-17F is produced by T H 17 cells in EAE 27 , suggesting that this group of people with multiple sclerosis have a disease that is skewed toward a T H 17 phenotype. Furthermore, these subjects also had high endogenous expression of IFN-β compared to responders. This correlation between high IL-17F and IFN-β concentrations in the serum suggests a tight biological association between these two cytokines. Two hypotheses, which may not be mutually exclusive, could explain this phenomenon. One hypothesis is that the nonresponders have aggressive T H 17-mediated disease, and, to counteract inflammation, their immune systems upregulate IFN-β. Since endogenous IFN-β expression is already high, IFN-β treatment is ineffective. A second hypothesis is that IFN-β is proinflammatory during T H 17-skewed disease. Not only would IFN-β treatment be ineffective, it could worsen symptoms. This is supported by observations in EAE where symptoms worsened with IFN-β treatment in T H 17-driven EAE, a finding concordant with the data in RRMS, where people with high IL-17F and IFN-β have exacerbated disease. Observations in neuromyelitis optica (NMO), another demyelinating disease, provide evidence for this hypothesis. NMO lesions are granulocytic 28, 29 , and T H 17 responses attract granulocytes to sites of inflammation [30] [31] [32] . Furthermore, people with NMO have high concentrations of IL-17 in the cerebrospinal fluid 33 . Finally, IFN-β treatment of NMO induces relapses 2, 34, 35 . Therefore, the disease processes of NMO and the IL-17F high nonresponders could be very similar.
The data presented in this study demonstrate a phenomenon often seen with cytokines. IFN-β has opposing effects in different contexts, leading to benefit in T H 1 conditions and harm in T H 17 conditions. This feature of IFN-β provides an opportunity to explore some logical biomarkers that might have predictive value in assessing the response to a popular therapy for multiple sclerosis.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. a r t i c l e s
